Quantum Genomics Société Anonyme (ALQGC.PA)

EUR 0.07

(0.0%)

Market Cap (In EUR)

4.99 Million

Revenue (In EUR)

19.79 Thousand

Net Income (In EUR)

-3.17 Million

Avg. Volume

844.34 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.001-0.155
PE
-
EPS
-
Beta Value
0.715
ISIN
FR0011648971
CUSIP
F76288111
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jean-Philippe Milon Ph.D.
Employee Count
-
Website
https://www.quantum-genomics.com
Ipo Date
2010-05-28
Details
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.